Search research articles
Contact Us
Filters
Showing results (41-50 of 52) with videos related to
Page
of 6
Sort By:
Gynecologic Oncology
|
October 13, 2019
Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers
S Intidhar Labidi-Galy, Thibault de La Motte Rouge, Olfa Derbel, et al.
BMC Medicine
|
December 11, 2025
Long-term quality of life in non-epithelial ovarian cancer survivors: TMRG-GINECO-Vivrovaire rare tumors case-control study
Coraline Dubot, Isabelle Ray-Coquard, Justine Lequesne, et al.
Gynecologic Oncology
|
May 21, 2023
Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients. A TMRG and GINECO group study
Brunhilde Hanvic, Fabrice Lecuru, Hélène Vanacker, et al.
Gynecologic Oncology
|
October 26, 2021
Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR)
Olivier Trédan, Magali Provansal, Cyril Abdeddaim, et al.
NPJ Genomic Medicine
|
April 23, 2026
Immuno-molecular features associated with exceptional recurrence-free survivorship from Ovarian Cancer in the pre-PARP era
Félix Blanc-Durand, Elisa Yaniz Galende, Gwénaël Ferron, et al.
BMC Cancer
|
October 27, 2021
"Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors"
François Gernier, Djihane Ahmed-Lecheheb, Patricia Pautier, et al.
The New England Journal of Medicine
|
July 3, 2024
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
Ignace Vergote, Antonio González-Martín, Keiichi Fujiwara, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 15, 2023
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
Rachel N Grisham, Ignace Vergote, Susana Banerjee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2020
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
Bradley J Monk, Rachel N Grisham, Susana Banerjee, et al.
BMJ Open
|
September 4, 2025
Clinical outcome of advanced or recurrent endometrial carcinoma treated with chemotherapy: a French observational retrospective cohort: the ENDOVIE study
Jerome Alexandre, Philippe Boudier, Elise Lavit, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 52) with videos related to
Sort By:
Page
of 6
Gynecologic Oncology
|
October 13, 2019
Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers
S Intidhar Labidi-Galy, Thibault de La Motte Rouge, Olfa Derbel, et al.
BMC Medicine
|
December 11, 2025
Long-term quality of life in non-epithelial ovarian cancer survivors: TMRG-GINECO-Vivrovaire rare tumors case-control study
Coraline Dubot, Isabelle Ray-Coquard, Justine Lequesne, et al.
Gynecologic Oncology
|
May 21, 2023
Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients. A TMRG and GINECO group study
Brunhilde Hanvic, Fabrice Lecuru, Hélène Vanacker, et al.
Gynecologic Oncology
|
October 26, 2021
Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR)
Olivier Trédan, Magali Provansal, Cyril Abdeddaim, et al.
NPJ Genomic Medicine
|
April 23, 2026
Immuno-molecular features associated with exceptional recurrence-free survivorship from Ovarian Cancer in the pre-PARP era
Félix Blanc-Durand, Elisa Yaniz Galende, Gwénaël Ferron, et al.
BMC Cancer
|
October 27, 2021
"Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors"
François Gernier, Djihane Ahmed-Lecheheb, Patricia Pautier, et al.
The New England Journal of Medicine
|
July 3, 2024
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
Ignace Vergote, Antonio González-Martín, Keiichi Fujiwara, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 15, 2023
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
Rachel N Grisham, Ignace Vergote, Susana Banerjee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2020
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
Bradley J Monk, Rachel N Grisham, Susana Banerjee, et al.
BMJ Open
|
September 4, 2025
Clinical outcome of advanced or recurrent endometrial carcinoma treated with chemotherapy: a French observational retrospective cohort: the ENDOVIE study
Jerome Alexandre, Philippe Boudier, Elise Lavit, et al.
Page
of 6